Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
-
Highlight
Notice to Convene Herantis Pharma Plc’s Annual General Meeting of Shareholders 30 March, 2026
-
Highlight
Herantis Pharma Plc Annual report 2025
-
Highlight
FY 2025 report webcast
-
Highlight
Herantis Pharma Phase 1b biomarker data webcast
-
Highlight
Topline Phase 1b data webcast
-
Highlight
Edison TV interview with Herantis CEO, Antti Vuolanto